

Respiratory Review of 2014: Tuberculosis and Nontuberculous Mycobacterial Pulmonary Disease

Cheol Kyu Park, M.D. and Yong Soo Kwon, M.D.

Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea

Since tuberculosis (TB) remains a major global health concern and the incidence of multi-drug resistant (MDR)-TB is increasing globally, new modalities for the detection of TB and drug resistant TB are needed to improve TB control. The Xpert MTB/RIF test can be a valuable new tool for early detection of TB and rifampicin resistance, with a high sensitivity and specificity. Late-generation fluoroquinolones, levofloxacin, and moxifloxacin, which are the principal drugs for the treatment of MDR-TB, show equally high efficacy and safety. Systemic steroids may reduce the overall TB mortality attributable to all forms of TB across all organ systems, although inhaled corticosteroids can increase the risk of TB development. Although fixed dose combinations were expected to reduce the risk of drug resistance and increase drug compliance, a recent meta-analysis found that they might actually increase the risk of relapse and treatment failure. Regarding treatment duration, patients with cavitation and culture positivity at 2 months of TB treatment may require more than 6 months of standard treatment. New anti-TB drugs, such as linezolid, bedaquiline, and delamanid, could improve the outcomes in drug-resistant TB. Nontuberculous mycobacterial lung disease has typical clinical and immunological phenotypes. Mycobacterial genotyping may predict disease progression, and whole genome sequencing may reveal the transmission of *Mycobacterium abscessus*. In refractory *Mycobacterium avium* complex lung disease, a moxifloxacin-containing regimen was expected to improve the treatment outcome.

Keywords: Tuberculosis; Nontuberculous Mycobacteria; Tuberculosis, Multidrug-Resistant; Diagnosis; Antitubercular Agents

Introduction

Tuberculosis (TB) remains a major global health concern, with 8.6 million incident cases and 1.3 million deaths in 2012¹. The emergence of multidrug resistant-TB (MDR-TB) and extensively drug resistant-TB (XDR-TB) pose a global risk to patients. MDR-TB is widespread, with an estimated 450,000 incident cases and 170,000 deaths, while XDR-TB has been reported in 92 countries during 2012¹. In Korea, the prevalence of bacteriologically or radiologically active TB (>5 years old) had decreased dramatically from 5,168/100,000 persons in 1965 to 767/100,000 persons in 1995². However, TB remains a current major health concern, since new cases have plateaued at approximately 100/100,000 persons over the past decade³. One possible explanation for the steady rate of new TB cases in Korea is that the aging population may have a higher risk

Address for correspondence: Yong Soo Kwon, M.D.

Department of Internal Medicine, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju 501-757, Korea

Phone: 82-62-220-6575, **Fax:** 82-62-225-8578

E-mail: yskwon@chonnam.ac.kr

Received: Jul. 4, 2014

Revised: Jul. 11, 2014

Accepted: Jul. 18, 2014

©It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>).

Copyright © 2014

The Korean Academy of Tuberculosis and Respiratory Diseases.

All rights reserved.

for TB development³.

Nontuberculous mycobacteria (NTM) are any mycobacterium other than *Mycobacterium tuberculosis* and *M. leprae*. NTM infection can cause 4 specific clinical manifestations, which are pulmonary disease, lymphadenitis, soft tissue and bone infections, and disseminated disease⁴. Among them, NTM pulmonary disease is the most common, comprising more than 90% of all NTM infections⁴. The incidence of chronic pulmonary disease, caused by NTM in human immunodeficiency virus (HIV)-negative patients, has also been increasing worldwide⁵. In Korea, NTM isolation in clinical specimens has been increasing, and has recently reached 47%–70% of positive mycobacterial cultures. The incidence of NTM lung disease has also increased^{6,9}.

This review covers important, recent clinical studies, especially those focused on diagnosis and treatment of drug-resistant TB, and the clinical manifestations and treatment for NTM pulmonary disease.

Tuberculosis

1. Xpert MTB/RIF test

Early detection and proper treatment can improve the outcomes of TB treatment, and are crucial for TB control programs. However, mycobacterial culture, which has the highest sensitivity and confirmative tool for diagnosis of active TB, requires 6 to 8 weeks for interpretation^{10,11}. Sputum smear microscopy is a rapid, simple, and inexpensive tool for diagnosis of active TB, and is highly specific in endemic areas. Unfortunately, it has low and variable sensitivity ranging between 20 and 60%^{12,13}.

Happily, recent advances in TB diagnosis have given hope for rapid detection of this disease. The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) (hereafter referred to as Xpert MTB/RIF) is a novel, rapid, automated, and cartridge-based nucleic acid amplification test which can detect TB, along with rifampicin resistance, directly from sputum within 2 hours¹⁴. The cartridges, named GeneXpert, are pre-loaded with all the necessary reagents for sample processing, DNA extraction, amplification, and laser detection of the amplified *rpoB* gene target¹⁴. The sensitivity and specificity of this test has been reported to be acceptable for TB detection. In a Cochrane database review of diagnostic accuracy, 27 studies were assessed, and the Xpert MTB/RIF pooled sensitivity was found to be 89% (95% confidence interval [CI], 85%–92%) and pooled specificity 99% (95% CI, 98%–99%)¹⁵. As a follow-up test for specimens with negative smear microscopy results, Xpert MTB/RIF pooled sensitivity was 67% (95% CI, 60%–74%), and pooled specificity was 99% (95% CI, 98%–99%)¹⁵. For rifampicin resistance detection, Xpert MTB/RIF showed an excellent

pooled sensitivity of 97% (95% CI, 90%–97%), and pooled specificity of 98% (95% CI, 97%–99%)¹⁵.

A major advantage of this test is that it can be accurately administered by unskilled nurses in primary-care clinics. In an African study of randomly assigned 758 TB patients, 'point-of-care' Xpert MTB/RIF testing administered by nurses had a higher sensitivity, and a similar specificity, compared to microscopy. Point-of care Xpert MTB/RIF test also had similar sensitivity, and higher specificity, compared to laboratory-based Xpert MTB/RIF testing¹⁶.

In a study conducted in South Korea, the Xpert MTB/RIF assay also showed similar results, with sensitivity of 79.5% and specificity of 100.0% in culture among 681 patients with suspected pulmonary TB¹⁷. Furthermore, the test decreased the median time to treatment, after initial evaluation, to 7 days (interquartile range [IQR], 4–9 days) vs. 21 days (IQR, 7–33.5 days)¹⁷. Therefore, Xpert MTB/RIF is a useful method for rapid detection of TB cases, as well as rifampin resistance, even in primary-care settings. The Xpert MTB/RIF also shortens the time to initiation of TB treatment.

2. Fluoroquinolones

Fluoroquinolones are the mainstay drugs for treatment of MDR-TB, and their efficacy has been established in many clinical studies¹⁸. They also have a potential role in reducing treatment duration in drug-susceptible TB¹⁹. Therefore, MDR-TB patients with additional resistance to fluoroquinolones have a worse prognosis. According to a meta-analysis by Falzon et al.²⁰, treatment success was lower in MDR-TB patients with resistance to fluoroquinolones alone (48%; 95% CI, 36%–60%) than in MDR-TB patients without additional resistance (64%; 95% CI, 57%–72%) or those with resistance to injectables alone (56%; 95% CI, 45%–66%).

Late-generation fluoroquinolones, such as levofloxacin and moxifloxacin, have been recommended in guidelines for the treatment of MDR-TB²¹. However, the superiority of these drugs for MDR-TB treatment is still unknown. Some experimental and animal studies have shown that moxifloxacin had lower minimal inhibitory concentrations, and higher bactericidal activity, compared to levofloxacin^{22,23}. However, high-dose levofloxacin (1,000 mg/day) showed an excellent early bactericidal activity, equivalent to that of moxifloxacin²⁴. Recently, the results of a prospective multicenter randomized trial in South Korea were published, in which moxifloxacin and levofloxacin (750 mg/day) were compared in the treatment of MDR-TB²⁵. According to this study, there was no difference in sputum cultures conversion (88.3% in levofloxacin group vs. 90.5% in moxifloxacin group, $p > 0.05$) or adverse drug events²⁵. Thus, these 2 drugs have been shown to have equivalently high efficacy and safety in the treatment of MDR-TB.

3. Steroids

Oral corticosteroids are well-known immunosuppressants, which can increase the risk of developing TB²⁶. However, whether inhaled corticosteroids (ICS) affect TB development remains unclear. Recently, 2 studies were published in South Korea examining this topic. First, a retrospective cohort study examined 616 patients with chronic obstructive pulmonary disease²⁷. Of all patients, 20 patients developed TB, and ICS users with suspicious radiologic sequelae (from prior pulmonary TB) in their chest radiographs had the highest risk for pulmonary TB (hazard ratio [HR], 24.95; 95% CI, 3.09–201.37; $p=0.003$)²⁷. Moreover, ICS users with normal chest radiographs also had increased an risk of pulmonary TB (HR, 9.08; 95% CI, 1.01–81.43; $p=0.049$)²⁷.

Second, Lee et al.²⁸ performed a nested case-control study, which included 4,139 matched patients with TB, and 20,583 control subjects among a total of 853,439 adults who had recently used inhaled respiratory medications, based on the database of the Health Insurance Review and Assessment Service (HIRA, Seoul, Korea). In their study, ICS use significantly increased the occurrence of TB (adjusted odds ratio, 1.20; 95% CI, 1.08–1.34), and a dose dependent relationship was also found ($p<0.001$ for trend)²⁸.

The effects of systemic steroids on TB have been described in TB meningitis and pericarditis^{29,30}. However, it has been unclear whether corticosteroid use can affect the mortality in patients with TB involving other organ. According to a recent meta-analysis of 41 trials, systemic steroids reduced overall mortality by 17% (risk ratio, 0.83; 95% CI, 0.74–0.92) across all organs³¹. However, it is worth noting that most trials took place before the era of the more effective rifampin-containing regimen. Therefore, HIV and MDR-TB infections, and the adverse events associated with corticosteroid treatment, cannot be ignored, and more convincing evidence is required to support the use of steroids to treat all forms of TB.

4. Fixed dose combination

Tablets of fixed-dose combination (FDC) are composed of 2 or more anti-TB drugs, and have been manufactured since the 1980s in order to improve medication compliance³². Since FDCs were also expected to reduce the risk of drug-resistant TB, by preventing inappropriate drug selection and monotherapy, the World Health Organization (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) recommended the use of these drugs in 1994^{33,34}. However, their efficacy is still controversial, due to the decreased bioavailability of rifampicin in FDCs³⁵. Recently, a systemic review and meta-analysis was performed to determine whether FDCs are effective in treating TB, and the results showed a trend toward higher risk of treatment failure or relapse with FDC use (pooled relative risk, 1.28; 95% CI,

0.99–1.7)³⁶. Given the possible risks, additional studies examining the effectiveness of FDCs are required.

5. Positive culture at 2 months of treatment and cavitation on baseline chest radiography

Although current TB drugs have existed for more than 40 years, and their high efficacy have been demonstrate in many studies, relapse rates for standard 6-month treatment of pulmonary TB were 1%–2% at 24 months after treatment³⁷. Unfortunately, there are no defined criteria for prolonging treatment to prevent a relapse of TB. In a recent study, the combination of cavitation on initial chest radiograph, and positive culture after 2 months, was associated with an increased risk of 1-year relapse, and the authors suggested an extension of treatment in these patients³⁸. However, this study was a single center retrospective study that included only 6 patients with TB relapse, and there was no proven efficacy of prolonged TB treatment in these patients. Further studies are needed to evaluate the efficacy of extending standard treatments.

Nontuberculous Mycobacterial Infection

1. Phenotypes of nontuberculous mycobacterial infection

NTM lung disease has 2 different radiographical manifestations: fibrocavitary and nodular bronchiectatic forms⁴. Fibrocavitary forms of NTM lung disease have cavitary lesions that typically involve the upper lobes, and have radiographic features similar to pulmonary TB⁴. There are some distinct characteristics of fibrocavitary NTM lung disease compared to pulmonary TB, including thin walled cavities with reduced surrounding parenchymal opacity, less bronchogenic with greater contiguous spread of disease, and a more marked involvement of pleura over the involved areas of the lungs. However, these were not sufficiently specific to NTM lung disease to be of diagnostic use⁴.

For patients with nodular bronchiectatic forms, both multifocal bronchiectasis and clusters of small nodules and branching linear structures are present in the mid and lower lung field⁴. In a study examining the frequency of NTM lung disease in 105 patients with bilateral bronchiectasis and bronchiolitis in their chest computed tomography, these characteristics were very specific for NTM lung disease, especially *Mycobacterium avium* complex (MAC) and *M. abscessus* infections. Bronchiolitis in more than 5 lobes with bronchiectasis, lobular consolidation, and cavitation were also related to NTM lung disease³⁹. However, it is important to note that there is considerable overlap in the radiographical manifestations of pulmonary TB and NTM lung disease, and radiographic findings alone could not differentiate the 2 diseases.

The clinical and immunological phenotypes of NTM lung

disease have recently been reported. Kartalija et al.⁴⁰ measured body morphotype, serum leptin, serum adiponectin, and several whole-blood cytokines in 103 patients with NTM lung disease, as well as 101 control subjects. Patients with NTM lung disease had significantly lower body mass index (BMI) and body fat, more prevalent scoliosis and pectus excavatum, and were taller stature than control subjects. Serum leptin and adiponectin less corresponded to body fat in patients with NTM lung disease, and interferon- γ and interleukin-10 levels were significantly suppressed in stimulated whole blood of these patients⁴⁰. These findings warrant further studies to clarify how specific morphotypes and immunophenotypes of NTM patients are responsible for developing disease. In a study reported by Lee et al.⁴¹, 84 patients with nodular bronchiectatic NTM lung disease were examined to evaluate morphotype, immunologic, and clinical characteristics. Similar to the findings of Kartalija et al.⁴⁰, Lee et al.⁴¹ found that patients with NTM had lower BMI and more scoliosis, compared to non-NTM bronchiectatic patients.

In addition to clinical and immunological phenotypes, mycobacterial genotyping may be capable of predicting clinical characteristics and prognoses in NTM lung disease. According to a study by Shin et al.⁴², patients with NTM lung disease caused by *M. abscessus* and *M. massiliense* were classified to 3 clusters on their variable number tandem repeat genotyping. In each cluster, patients had similar clinical courses and prognoses; a stable nodular bronchiectatic form which had no NTM treatment >24 months after diagnosis, a progressive nodular bronchiectatic form which had NTM treatment within 24 months, and a fibrocavitary form which had NTM treatment immediately after diagnosis⁴². Furthermore, in a study using whole-genome sequencing for *M. abscessus* isolates from patients with cystic fibrosis, it was found that the route of transmission was inter-patient, confirmed by less diverse variation in phylogenetic analysis among patients. These findings were confirmed by the fact that multidrug-resistant species were isolated from several patients who had been never previously exposed to drugs, indicating cross-infection⁴³.

2. Treatment of refractory MAC pulmonary disease

For the treatment of MAC infection, macrolide antibiotics, such as clarithromycin and azithromycin, are crucial treatments, and clinical outcomes are significantly correlated with *in vitro* susceptibility to clarithromycin⁴. Therefore, American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guidelines recommend regimens consist of clarithromycin or azithromycin, ethambutol, and rifampin for treatment of this disease⁴. The efficacy of this regimen has shown up to 80% of negative culture conversion^{44,45}.

However, if patients have are resistant to macrolide, or have failed to respond to treatments including macrolide in the previous 6 months, the treatment is very difficult⁴⁶. Risk factors for

macrolide-resistant infection include macrolide monotherapy or regimens containing 2 drugs⁴⁶, and poor physician adherence to NTM treatment guidelines may also contribute⁴⁷. In a recent study by Koh et al.⁴⁸, 41 patients with persistent positive culture after at least 6 months of macrolide-based standardized therapy were recruited to evaluate the clinical efficacy of a moxifloxacin-containing regimen. All 41 patients were treated with a moxifloxacin-containing regimen, and the overall treatment success rate was 29% (12/41), indicating that moxifloxacin may improve treatment outcomes for refractory MAC lung disease⁴⁸. However, this was a single-center, retrospective study with small number of enrolled patients. Prospective randomized control studies are required to clarify the clinical efficacy of moxifloxacin for refractory MAC lung disease.

Conclusion

The emergence of drug-resistant TB is an increasing global health concern. Early detection of TB and drug resistance is important for TB control programs, and the Xpert MTB/RIF test could be a useful tool in this field. Levofloxacin and moxifloxacin are equally safe and efficacious in the treatment of MDR-TB. ICS could be a risk factor of the development of active TB, and systemic administration of corticosteroids may decrease mortality in all forms of active TB. Positive culture at 2 months of treatment, and cavitation on baseline chest radiography, could indicate a risk of TB relapse, and may require prolonged treatment. NTM pulmonary disease has typical clinical phenotypes, and moxifloxacin may improve treatment outcomes in refractory MAC pulmonary disease.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. World Health Organization. Global tuberculosis report 2013 [Internet]. Geneva: World Health Organization; 2013 [cited 23 Oct 2013]. Available from: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf.
2. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. *Int J Tuberc Lung Dis* 1998;2:27-36.
3. Park YK, Park YS, Na KI, Cho EH, Shin SS, Kim HJ. Increased tuberculosis burden due to demographic transition in Korea from 2001 to 2010. *Tuberc Respir Dis* 2013;74:104-10.
4. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis,

- treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007;175:367-416.
5. Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. *Semin Respir Crit Care Med* 2013;34:87-94.
 6. Yoo JW, Jo KW, Kim MN, Lee SD, Kim WS, Kim DS, et al. Increasing trend of isolation of non-tuberculous mycobacteria in a tertiary university hospital in South Korea. *Tuberc Respir Dis* 2012;72:409-15.
 7. Park YS, Lee CH, Lee SM, Yang SC, Yoo CG, Kim YW, et al. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. *Int J Tuberc Lung Dis* 2010;14:1069-71.
 8. Lee SK, Lee EJ, Kim SK, Chang J, Jeong SH, Kang YA. Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea. *Scand J Infect Dis* 2012;44:733-8.
 9. Koh WJ, Chang B, Jeong BH, Jeon K, Kim SY, Lee NY, et al. Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea. *Tuberc Respir Dis* 2013;75:199-204.
 10. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. *Am J Respir Crit Care Med* 2000;161(4 Pt 1):1376-95.
 11. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. *Lancet Infect Dis* 2003;3:288-96.
 12. Aber VR, Allen BW, Mitchison DA, Ayuma P, Edwards EA, Keyes AB. Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. *Tubercle* 1980;61:123-33.
 13. Urbanczik R. Present position of microscopy and of culture in diagnostic mycobacteriology. *Zentralbl Bakteriell Mikrobiol Hyg A* 1985;260:81-7.
 14. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Publication number WHO/HTM/TB/2011.4. Geneva: World Health Organization; 2011.
 15. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev* 2013;1:CD009593.
 16. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. *Lancet* 2014;383:424-35.
 17. Kwak N, Choi SM, Lee J, Park YS, Lee CH, Lee SM, et al. Diagnostic accuracy and turnaround time of the Xpert MTB/RIF assay in routine clinical practice. *PLoS One* 2013;8:e77456.
 18. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. *PLoS Med* 2012;9:e1001300.
 19. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2008;12:128-38.
 20. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. *Eur Respir J* 2013;42:156-68.
 21. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: World Health Organization; 2011.
 22. Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. *Am J Respir Crit Care Med* 2013;188:97-102.
 23. Cremades R, Rodriguez JC, Garcia-Pachon E, Galiana A, Ruiz-Garcia M, Lopez P, et al. Comparison of the bactericidal activity of various fluoroquinolones against *Mycobacterium tuberculosis* in an *in vitro* experimental model. *J Antimicrob Chemother* 2011;66:2281-3.
 24. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2006;10:605-12.
 25. Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for multi-drug-resistant tuberculosis. *Am J Respir Crit Care Med* 2013;188:858-64.
 26. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. *Arthritis Rheum* 2006;55:19-26.
 27. Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. *Chest* 2013;143:1018-24.
 28. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. *Thorax* 2013;68:1105-13.
 29. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. *Cochrane Database Syst Rev* 2008; CD002244.
 30. Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. *Cochrane Database Syst Rev* 2002;(4):CD000526.
 31. Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a system-

- atic review and meta-analysis. *Lancet Infect Dis* 2013;13:223-37.
32. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med* 2007;120:713-9.
33. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. *Bull World Health Organ* 2001;79:61-8.
34. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. *Tuber Lung Dis* 1994;75:180-1.
35. Milan-Segovia RC, Dominguez-Ramirez AM, Jung-Cook H, Magana-Aquino M, Romero-Mendez MC, Medellin-Garibay SE, et al. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. *Int J Tuberc Lung Dis* 2010;14:1454-60.
36. Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. *Eur Respir J* 2013;42:721-32.
37. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. *Am J Respir Crit Care Med* 2004;170:1124-30.
38. Jo KW, Yoo JW, Hong Y, Lee JS, Lee SD, Kim WS, et al. Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. *Respir Med* 2014;108:654-9.
39. Koh WJ, Lee KS, Kwon OJ, Jeong YJ, Kwak SH, Kim TS. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. *Radiology* 2005;235:282-8.
40. Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, et al. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. *Am J Respir Crit Care Med* 2013;187:197-205.
41. Lee AR, Lee J, Choi SM, Seong MW, Kim SA, Kim M, et al. Phenotypic, immunologic, and clinical characteristics of patients with nontuberculous mycobacterial lung disease in Korea. *BMC Infect Dis* 2013;13:558.
42. Shin SJ, Choi GE, Cho SN, Woo SY, Jeong BH, Jeon K, et al. Mycobacterial genotypes are associated with clinical manifestation and progression of lung disease caused by *Mycobacterium abscessus* and *Mycobacterium massiliense*. *Clin Infect Dis* 2013;57:32-9.
43. Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, et al. Whole-genome sequencing to identify transmission of *Mycobacterium abscessus* between patients with cystic fibrosis: a retrospective cohort study. *Lancet* 2013;381:1551-60.
44. Kim EY, Chi SY, Oh IJ, Kim KS, Kim YI, Lim SC, et al. Treatment outcome of combination therapy including clarithromycin for *Mycobacterium avium* complex pulmonary disease. *Korean J Intern Med* 2011;26:54-9.
45. Sim YS, Park HY, Jeon K, Suh GY, Kwon OJ, Koh WJ. Standardized combination antibiotic treatment of *Mycobacterium avium* complex lung disease. *Yonsei Med J* 2010;51:888-94.
46. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al. Clinical and molecular analysis of macrolide resistance in *Mycobacterium avium* complex lung disease. *Am J Respir Crit Care Med* 2006;174:928-34.
47. Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. *Ann Am Thorac Soc* 2014;11:9-16.
48. Koh WJ, Hong G, Kim SY, Jeong BH, Park HY, Jeon K, et al. Treatment of refractory *Mycobacterium avium* complex lung disease with a moxifloxacin-containing regimen. *Antimicrob Agents Chemother* 2013;57:2281-5.